Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Fuse Oncology, Inc.Fuse Oncology to Showcase S!GNAL Workflow Experience at ASTRO 2026Potential workflow illustrates how patient workflow coordination in GE HealthCare's Intelligent Radiation Therapy™ (iRT) software solution could connect to targeted charge review in S!GNAL — Fuse Oncology today announced plans to showcase a...
- IASO Bio2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in...
- The Rosen Law Firm PACAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 DeadlineInvestors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options
- The Rosen Law Firm PAROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- CAPR FINAL DEADLINE: ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
- SPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
- The Rosen Law Firm PASPRY DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- AARD FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Advises Unicycive Therapeutics, Inc. (UNCY) Investors to Act Before the Lead Plaintiff Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may...
- Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.Robbins LLP is Investigating Allegations that ARS Pharmaceuticals Misled Investors Regarding Their Business Prospects